Genes May Protect Against APOE4 Alzheimer’s Risk

TL;DR

Prime Big Deal Days · Oct 6–7Offer from Amazon

Get health and wellness essentials delivered free — and shop member deals

• Fast, free delivery on millions of items
• Access to Prime Big Deal Days deals on October 6–7
• Prime Video, Amazon Music and more included

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

Researchers analyzing genetic data from nearly 450,000 people identified 42 DNA regions associated with Alzheimer’s risk among people carrying APOE4, including 29 regions not previously reported. The results point to genes active in oligodendrocytes as possible protective factors, but they do not establish that these genes prevent disease or that the findings apply across populations.

Researchers analyzing genetic data from nearly 450,000 people identified 42 DNA regions associated with Alzheimer’s risk among people who carry the APOE4 variant, including 29 regions not previously reported in this analysis. The findings, published in Alzheimer’s & Dementia, point to genes active in oligodendrocytes as possible modifiers of risk, but they do not show that those genes prevent the disease or provide a treatment.

The study, led by Michael Belloy, an assistant professor at Washington University in St. Louis, focused on genetic factors that may alter the risk associated with carrying one or two copies of APOE4. APOE4 is a major common genetic risk factor for Alzheimer’s, but carrying it does not mean a person will inevitably develop the disease. The researchers examined why some carriers in the study had no Alzheimer’s diagnosis despite their elevated genetic risk.

The team identified 42 DNA regions linked to APOE4-related risk: 13 had been identified in previous work and 29 were new in this analysis. The researchers also examined gene activity in post-mortem brain tissue from 424 donors. Several genes associated with protection were active in oligodendrocytes, cells that form insulating sheaths around nerve fibers and help electrical signals travel efficiently.

Belloy highlighted TNS3 and CISD1 as genes that may be relevant. The source report says TNS3 is involved in oligodendrocyte maturation and survival, while CISD1 is important to their metabolism. These are candidate mechanisms, not confirmed drug targets: the report says there are no FDA-approved medicines targeting these genes that could be repurposed for Alzheimer’s.

Oligodendrocytes Offer a New Lead

The findings add to evidence that Alzheimer’s risk is shaped by more than APOE4 alone. If further research confirms that some genetic variants reduce risk by changing oligodendrocyte function, those cells could become a focus for studies of disease biology and future drug development. That possibility matters because it may point researchers toward processes different from the better-known focus on amyloid and tau.

The results do not establish that increasing the activity of TNS3, CISD1, or other candidate genes would lower risk in people. Belloy told Being Patient that individual genetic effects may be small, while suggesting that treatments could potentially build on protective pathways. That is a research proposition, not evidence that a therapy based on these findings works.

The report also notes a possible link to MAPT, the gene that provides instructions for tau. Laura Nisenbaum, chief scientific officer of the Alzheimer’s Drug Discovery Foundation and not involved in the study, said she found the association between higher MAPT activity and protection interesting. She noted a possible connection to Biogen’s diranersen, a tau gene-silencing therapy heading toward Phase 3 trials. The study does not show that its result predicts diranersen’s effectiveness or supports its use.

How APOE4 Shapes Risk

APOE4 is associated with a substantially increased chance of Alzheimer’s, but genetic risk is not certainty. The Being Patient report says the risk can increase four- to 12-fold, depending on a person’s APOE4 status. It also reports that about 60% of people with two copies develop Alzheimer’s over their lifetimes, underscoring that even this higher-risk group does not all receive a diagnosis.

Researchers have previously studied rare genetic variants that appear to offer protection, including the Christchurch variant in a family with inherited Alzheimer’s. The current research takes a broader approach by looking for genetic regions that may modify risk among APOE4 carriers. Such studies can help identify biological pathways for later testing, but associations in genetic data need replication and experimental work before they can support clinical conclusions.

“Ultimately, we found a set of genes that look promising to counter Alzheimer’s disease risk due to APOE4.”

— Michael Belloy, assistant professor at Washington University in St. Louis, speaking to Being Patient

Findings Need Broader Validation

The study identifies associations; it does not establish that the highlighted genes directly cause protection. The report says the genetic sample was made up mostly of people of European ancestry, so it is unclear whether the findings generalize to other populations. The researchers also relied on clinical diagnoses, and only 40% of participants had biomarker confirmation, leaving possible diagnostic misclassification as a limitation.

The brain tissue analysis raises a separate timing question. Tissue from the 424 donors was collected after death, and Nisenbaum cautioned that samples from people who died in later disease stages may not represent what happens earlier. It is also unknown whether the observed gene activity is protective, a response to disease, or related to other factors. The report says the genetic signals still require validation and experimental testing.

Replication Before Treatment Claims

The next steps are replication in additional groups and laboratory experiments that test whether the candidate genes alter relevant brain-cell processes or Alzheimer’s risk. Those studies could clarify whether oligodendrocytes are part of a protective pathway and whether TNS3, CISD1, or other genes are practical targets for drug development.

For now, the work is an early-stage contribution to genetic research, not a change to Alzheimer’s screening or treatment. The report gives no timeline for follow-up validation, and it does not say that a medicine targeting these genes is in clinical testing. Researchers will need stronger evidence about mechanisms, population differences, and the timing of gene activity before the findings can inform patient care.

Key Questions

Does carrying APOE4 mean someone will develop Alzheimer’s?

No. APOE4 is associated with higher risk, but it does not make Alzheimer’s inevitable. The report says about 60% of people with two copies develop the disease over their lifetimes.

Which genes did the study highlight?

The report names TNS3 and CISD1 as possible risk modifiers and also discusses MAPT gene activity. These are research candidates, not confirmed protective genes or established treatment targets.

Does the study show that these genes prevent Alzheimer’s?

No. It found genetic associations that may modify APOE4-related risk. Further validation and experiments are needed to determine whether the genes directly affect protection.

Could the findings lead to a new Alzheimer’s drug?

Potentially, but no drug benefit was demonstrated. The report says there are no FDA-approved medicines targeting TNS3 or CISD1 that can currently be repurposed for Alzheimer’s.

Do the results apply to people of every ancestry?

That is not yet known. Most participants were of European ancestry, so studies in more diverse populations are needed to assess how broadly the findings apply.

Source: rss